Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease

Immunovant's Phase 3 studies of batoclimab for thyroid eye disease (TED) did not meet their primary endpoint related to proptosis responder rates. However, safety results were consistent with previous findings, and patients showed greater proptosis improvement during the initial high-dose period. The company is now focusing on advancing IMVT-1402 across multiple indications.